Spots Global Cancer Trial Database for Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases

Official Title: Role of CD3+ and NKp46+ Cells in Resected Colorectal Liver Metastases.

Study ID: NCT02615665

Conditions

Colorectal Liver Metastases

Interventions

Hepatic resection

Study Description

Brief Summary: The long-term outcome of patients resected for colorectal liver metastases (CLM) after neoadjuvant chemotherapy (CHT) depends by several tumoral and non-tumoral factors, such as the immune response to the tumor and to the CHT. The aim of this study was to investigate the impact of the pathological and immunological response in patients undergoing liver resection for CLM after CHT in regards to the long-term outcome.

Detailed Description: The immunoreactivity to CD3+ and NKp46+ cells inside the tumor, at the border between the tumor and the normal liver, and inside the normal liver will be tested by computer-assisted image analyses in patients undergoing liver resection for CLM between 2005 and 2013 preoperatively treated with oxaliplatin or irinotecan with or without bevacizumab or cetuximab. The survival will be assessed in relation to several prognostic factors and to that immunoreactivity.